Strategies to Overcome HLA Sensitization and Improve Access to Retransplantation after Kidney Graft Loss
暂无分享,去创建一个
A. Martinho | H. Sá | R. Alves | R. Leal | Clara Pardinhas | A. Figueiredo | C. Pardinhas
[1] F. Claas,et al. European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group , 2022, Transplant International.
[2] C. Couchoud,et al. Association between kidney retransplantation and survival according to age in the French national cohort of dialysis patients , 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] H. Sá,et al. Kidney Retransplant: Not Too Old for a Second Chance. , 2022, Transplantation proceedings.
[4] Christine A. White,et al. Immunosuppressant Medication Use in Patients with Kidney Allograft Failure: A Prospective Multicenter Canadian Cohort Study , 2022, Journal of the American Society of Nephrology : JASN.
[5] A. Israni,et al. OPTN/SRTR 2020 Annual Data Report: Kidney , 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] B. Kiberd,et al. Disparities in Access to Preemptive Repeat Kidney Transplant: Still Missing the Mark? , 2021, Kidney360.
[7] D. Abramowicz,et al. Waiting Time for Second Kidney Transplantation and Mortality , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[8] L. Cantwell,et al. Prolonged immunosuppression does not improve risk of sensitization or likelihood of retransplantation after kidney transplant graft failure , 2021, Transplant international : official journal of the European Society for Organ Transplantation.
[9] P. Nickerson,et al. Significance of HLA-DQ in kidney transplantation - Time to re-evaluate HLA matching priorities to improve transplant outcomes? An expert review and recommendations. , 2021, Kidney international.
[10] F. Claas,et al. Highly Sensitized Patients Are Well Served by Receiving a Compatible Organ Offer Based on Acceptable Mismatches , 2021, Frontiers in Immunology.
[11] J. Friedewald,et al. The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] S. Knechtle,et al. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization , 2021, Frontiers in Immunology.
[13] D. Segev,et al. Evolving Trends in Risk Profiles and Outcomes in Older Adults Undergoing Kidney Retransplantation , 2021, Transplantation.
[14] J. Schold,et al. Association Between Donor-Recipient Biological Relationship and Allograft Outcomes After Living Donor Kidney Transplant , 2021, JAMA network open.
[15] M. Crespo,et al. Stratifying the humoral risk of candidates to a solid organ transplantation: a proposal of the ENGAGE working group , 2021, Transplant international : official journal of the European Society for Organ Transplantation.
[16] J. Friedewald,et al. Kidney recipients with allograft failure, transition of kidney care (KRAFT): A survey of contemporary practices of transplant providers , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] L. Lobato,et al. Eplet-based virtual PRA increases transplant probability in highly-sensitized patients. , 2021, Transplant immunology.
[18] S. Fuggle,et al. A Europe wide acceptable mismatch program will enable transplantation of long waiting highly sensitised patients with a compatible donor. , 2020, Transplant immunology.
[19] B. Lonze. A review of imlifidase in solid organ transplantation , 2020, Expert opinion on biological therapy.
[20] C. Thongprayoon,et al. Outcomes of kidney retransplantation in recipients with prior posttransplant lymphoproliferative disorders: An analysis of the 2000–2019 UNOS/OPTN database , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[21] R. Montgomery,et al. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes) , 2020, Transplantation.
[22] V. Kher,et al. Paired kidney exchange transplantation – pushing the boundaries , 2020, Transplant international : official journal of the European Society for Organ Transplantation.
[23] A. Courtney,et al. Living Donor Kidney Transplantation Improves Graft and Recipient Survival in Patients with Multiple Kidney Transplants , 2020, Journal of clinical medicine.
[24] C. Ahn,et al. Weaning Immunosuppressant in Patients with Failing Kidney Grafts and The Outcomes: A Single-Center Retrospective Cohort Study , 2020, Scientific Reports.
[25] Rachel J. Johnson,et al. Overview of the Evolution of the UK Kidney Allocation Schemes , 2020, Current Transplantation Reports.
[26] D. Roelen,et al. Donor-specific B Cell Memory in Alloimmunized Kidney Transplant Recipients: First Clinical Application of a Novel Method , 2020, Transplantation.
[27] C. Thongprayoon,et al. Outcomes of kidney retransplantation after graft loss as a result of BK virus nephropathy in the era of newer immunosuppressant agents , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[28] J. Gill,et al. Access to Kidney Transplantation after a Failed First Kidney Transplant and Associations with Patient and Allograft Survival: An Analysis of National Data to Inform Allocation Policy. , 2019, Clinical journal of the American Society of Nephrology : CJASN.
[29] R. Redfield,et al. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] M. Bots,et al. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[31] J. Hodson,et al. Outcomes in Third and Fourth Kidney Transplants Based on the Type of Donor. , 2019, Transplantation.
[32] M. Metzger,et al. Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. , 2019, Kidney international.
[33] G. Lucisano,et al. Allosensitization after transplant failure: the role of graft nephrectomy and immunosuppression – a retrospective study , 2019, Transplant international : official journal of the European Society for Organ Transplantation.
[34] Douglas E Schaubel,et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[35] M. Naesens,et al. Indications, risks and impact of failed allograft nephrectomy. , 2019, Transplantation reviews.
[36] L. Henderson,et al. The Impact of Withdrawal of Maintenance Immunosuppression and Graft Nephrectomy on HLA Sensitization and Calculated Chance of Future Transplant , 2018, Transplantation direct.
[37] A. Waterman,et al. The first 9 years of kidney paired donation through the National Kidney Registry: Characteristics of donors and recipients compared with National Live Donor Transplant Registries , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[38] F. Claas,et al. How the definition of acceptable antigens and epitope analysis can facilitate transplantation of highly sensitized patients with excellent long-term graft survival , 2018, Current opinion in organ transplantation.
[39] P. Nickerson,et al. A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity , 2018, Transplantation.
[40] N. Kamar,et al. Preemptive second kidney transplantation is associated with better graft survival compared with non‐preemptive second transplantation: a multicenter French 2000–2014 cohort study , 2018, Transplant international : official journal of the European Society for Organ Transplantation.
[41] J. Malheiro,et al. Clinical implications of anti-HLA antibodies testing in kidney transplantation , 2018 .
[42] S. Jordan,et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. , 2017, The New England journal of medicine.
[43] R. Bray,et al. Understanding solid-phase HLA antibody assays and the value of MFI. , 2017, Human immunology.
[44] A. Cabrita,et al. Increase of allosensitization after a kidney graft failure: Predictors and effect on retransplantation outcomes. , 2017, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
[45] Byron H. Smith,et al. 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody , 2017, Transplantation.
[46] Rachel J. Johnson,et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis , 2017, The Lancet.
[47] M. Salifu,et al. Mortality after Renal Allograft Failure and Return to Dialysis , 2017, American Journal of Nephrology.
[48] R. Redfield,et al. The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[49] S. Chadban,et al. Waiting Time Between Failure of First Graft and Second Kidney Transplant and Graft and Patient Survival , 2016, Transplantation.
[50] J. Slaven,et al. Re‐transplants compared to primary kidney transplants recipients: a mate kidney paired analysis of the OPTN/UNOS database , 2016, Clinical transplantation.
[51] M. Stegall,et al. Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. , 2016, The New England journal of medicine.
[52] B. Chung,et al. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients , 2016, Medicine.
[53] John Gill,et al. Re-Examining Risk of Repeated HLA Mismatch in Kidney Transplantation. , 2016, Journal of the American Society of Nephrology : JASN.
[54] C. Ahn,et al. Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation , 2016, Medicine.
[55] J. Ijzermans,et al. Improving the outcome of kidney transplantation by ameliorating renal ischemia reperfusion injury: lost in translation? , 2016, Journal of Translational Medicine.
[56] I. Feurer,et al. Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study , 2016, Transplantation direct.
[57] Ashesh P. Shah,et al. Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized , 2016, Clinical transplantation.
[58] F. Diekmann,et al. Pre-Emptive Retransplantation in Patients With Chronic Kidney Graft Failure. , 2015, Transplantation proceedings.
[59] Wai H Lim,et al. Kidney paired donation: principles, protocols and programs. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[60] Tongyu Lin,et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. , 2014, JAMA.
[61] L. Sharples,et al. Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation. , 2014, Kidney international.
[62] D. Roelen,et al. Immunogenetics and immunology of transplantation in Leiden. , 2014, Transplant immunology.
[63] A. Courtney,et al. Factors influencing survival after kidney transplant failure , 2014, Transplantation research.
[64] R. Bray,et al. HLA Antibody Detection With Solid Phase Assays: Great Expectations or Expectations Too Great? , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[65] M. Haas,et al. Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients , 2014, Transplantation.
[66] J. Schold,et al. Risk Factors for Retransplant Kidney Recipients: Relisting and Outcomes From Patients' Primary Transplant , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[67] M. Zeier,et al. Influence of Test Technique on Sensitization Status of Patients on the Kidney Transplant Waiting List , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[68] A. Stiggelbout,et al. Difference in quality of life, fatigue and societal participation between living and deceased donor kidney transplant recipients , 2013, Clinical transplantation.
[69] J. Petrozzino,et al. Efficacy, Outcomes, and Cost-Effectiveness of Desensitization Using IVIG and Rituximab , 2013, Transplantation.
[70] J. Gill,et al. Risks and Benefits of Preemptive Second Kidney Transplantation , 2013, Transplantation.
[71] J. Perl,et al. Reduced survival and quality of life following return to dialysis after transplant failure: the Dialysis Outcomes and Practice Patterns Study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[72] M. Salvadori,et al. Renal transplant allocation criteria, desensitization strategies and immunosuppressive therapy in retransplant renal patients. , 2012, Journal of nephrology.
[73] D. Hricik,et al. Independent of Nephrectomy, Weaning Immunosuppression Leads to Late Sensitization After Kidney Transplant Failure , 2012, Transplantation.
[74] L. Rostaing,et al. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[75] P. Terasaki,et al. Durability of Antibody Removal Following Proteasome Inhibitor-Based Therapy , 2012, Transplantation.
[76] J. Pober,et al. Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells , 2011, The Journal of Immunology.
[77] M. Stegall,et al. Terminal Complement Inhibition Decreases Antibody‐Mediated Rejection in Sensitized Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[78] R. Montgomery,et al. Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients , 2011, Current opinion in organ transplantation.
[79] L. Kucirka,et al. Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.
[80] T. Kozłowski,et al. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? , 2011, Annals of transplantation.
[81] A. Lu,et al. Desensitization protocols and their outcome. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[82] E. Thervet,et al. Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study , 2010, Transplantation.
[83] S. Jordan,et al. Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation , 2010, Transplantation.
[84] A. Zachary,et al. Immunogenetics and immunology in transplantation , 2010, Immunologic research.
[85] S. Jameson,et al. Diversity in T cell memory: an embarrassment of riches. , 2009, Immunity.
[86] J. Schold,et al. A Lifetime Versus a Graft Life Approach Redefines the Importance of HLA Matching in Kidney Transplant Patients , 2009, Transplantation.
[87] S. Jordan,et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.
[88] D. Schaubel,et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[89] D. Schaubel,et al. Evaluating the Survival Benefit of Kidney Retransplantation , 2006, Transplantation.
[90] M. Stegall,et al. A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[91] M. Tonelli,et al. Why Do Preemptive Kidney Transplant Recipients Have an Allograft Survival Advantage? , 2004, Transplantation.
[92] R. Jofré,et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. , 2004, Journal of the American Society of Nephrology : JASN.
[93] I. Doxiadis,et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. , 2004, Transplantation.
[94] I. Doxiadis,et al. THE ACCEPTABLE MISMATCH PROGRAM AS A FAST TOOL TO TRANSPLANT HIGHLY SENSITISED PATIENTS AWAITING A CADAVER KIDNEY: SHORT WAITING TIME AND EXCELLENT GRAFT OUTCOME. , 2004 .
[95] J. Cambier,et al. B lymphocyte activation during cognate interactions with CD4+ T lymphocytes: molecular dynamics and immunologic consequences. , 2003, Seminars in immunology.
[96] J. Soulillou,et al. Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months. , 2003, Kidney international.
[97] Rene J. Duquesnoy,et al. HLA MATCHMAKER: A MOLECULARLY BASED ALGORITHM FOR HISTOCOMPATIBILITY DETERMINATION , 2003 .
[98] A. Kausz,et al. Mortality after kidney transplant failure: the impact of non-immunologic factors. , 2002, Kidney international.
[99] René J Duquesnoy,et al. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. , 2002, Human immunology.
[100] B. Kasiske,et al. Preemptive kidney transplantation: the advantage and the advantaged. , 2002, Journal of the American Society of Nephrology : JASN.
[101] R. Zietse,et al. Immunosuppression should be stopped in patients with renal allograft failure , 2001, Clinical transplantation.
[102] R. Wolfe,et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. , 1998, Transplantation.
[103] M. Fishbein,et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. , 1998, Transplantation.
[104] F. Claas,et al. Repeated HLA mismatches in cadaveric renal transplantation: is it safe to transplant? , 1997, Transplantation proceedings.
[105] A. Matas,et al. Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival? , 1996, Clinical transplantation.
[106] G. Nyberg,et al. Renal retransplantation in patients with HLA‐antibodies , 1992 .
[107] G. Nyberg,et al. Renal retransplantation in patients with HLA-antibodies. , 1992, Transplant International.